We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+6.32%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$16.2B
AUM Growth
+$1.75B
Cap. Flow
+$1.1B
Cap. Flow %
6.8%
Top 10 Hldgs %
54.17%
Holding
115
New
28
Increased
36
Reduced
22
Closed
20

Top Buys

Rank Stock Value
1
AABA
Altaba Inc
AABA
+$784M
2
ESRX
Express Scripts Holding Company
ESRX
+$504M
3
GD icon
General Dynamics
GD
+$348M
4
XL
XL Group Ltd.
XL
+$329M
5
KDP icon
Keurig Dr Pepper
KDP
+$194M

Top Sells

Rank Stock Value
1
NXPI icon
NXP Semiconductors
NXPI
+$618M
2
MON
Monsanto Co
MON
+$543M
3
COL
Rockwell Collins
COL
+$151M
4
ABLX
Ablynx NV
ABLX
+$134M
5
PPLI
People Inc
PPLI
+$112M

Sector Composition

Rank Sector Weight
1 Healthcare 20.57%
2 Technology 19.02%
3 Financials 14.39%
4 Communication Services 11.79%
5 Industrials 10.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TFCF
26
DELISTED
Twenty-First Century Fox, Inc. Class B
TFCF
$174M 1.08%
3,537,500
-1,462,500
-29% -$57.2M
CTXS
27
DELISTED
Citrix Systems Inc
CTXS
$167M 1.03%
1,594,570
-719,684
-31% -$74.1M
LBTYK icon
28
Liberty Global Class C
LBTYK
$3.55B
$147M 0.91%
5,522,656
+624,563
+13% +$18.2M
LBTYA icon
29
Liberty Global Class A
LBTYA
$3.63B
$147M 0.91%
5,327,493
+613,567
+13% +$18.5M
AZN icon
30
AstraZeneca
AZN
$257B
$135M 0.83%
1,925,000
+142,500
+8% +$10.3M
ENTA icon
31
Enanta Pharmaceuticals
ENTA
$392M
$125M 0.77%
1,075,000
+160,000
+17% +$16M
RDUS
32
DELISTED
Radius Health, Inc.
RDUS
$120M 0.74%
4,086,300
– –
CI icon
33
Cigna
CI
$73.3B
$114M 0.7%
671,000
+491,000
+273% +$85M
KYNB
34
Kyntra Bio
KYNB
$30.4M
$108M 0.66%
68,700
– –
EFX icon
35
Equifax
EFX
$22.6B
$105M 0.65%
838,959
-565,869
-40% -$67.1M
GGP
36
DELISTED
GGP Inc.
GGP
$104M 0.64%
+5,085,000
New +$103M
SAGE
37
DELISTED
Sage Therapeutics
SAGE
$97.8M 0.6%
625,000
+180,000
+40% +$28.3M
ASND icon
38
Ascendis Pharma A/S
ASND
$16.6B
$96.9M 0.6%
1,457,297
+170,497
+13% +$11.2M
ANDV
39
DELISTED
Andeavor
ANDV
$80M 0.49%
+610,000
New +$80.3M
ARRY
40
DELISTED
Array Biopharma Inc
ARRY
$78M 0.48%
4,650,000
+1,555,000
+50% +$24.7M
ZGNX
41
DELISTED
Zogenix, Inc.
ZGNX
$74.9M 0.46%
1,695,500
+119,500
+8% +$4.93M
MYOK
42
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$73.5M 0.45%
1,481,278
+442,000
+43% +$21.4M
BIIB icon
43
Biogen
BIIB
$32B
$72.3M 0.45%
249,000
-91,000
-27% -$25.6M
XLRN
44
DELISTED
Acceleron Pharma
XLRN
$68M 0.42%
1,401,000
– –
TFCFA
45
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
$61.4M 0.38%
+1,235,000
New +$48.8M
AVA icon
46
Avista
AVA
$3.15B
$58.5M 0.36%
1,111,723
+711,723
+178% +$37.2M
FOLD
47
DELISTED
Amicus Therapeutics
FOLD
$57.1M 0.35%
3,655,000
+174,000
+5% +$2.63M
IOVA icon
48
Iovance Biotherapeutics
IOVA
$3.76B
$56.6M 0.35%
4,425,000
+275,000
+7% +$4.02M
SINA
49
DELISTED
Sina Corp
SINA
$53.8M 0.33%
+635,000
New +$59.1M
GBT
50
DELISTED
Global Blood Therapeutics, Inc.
GBT
$53.6M 0.33%
+1,185,000
New +$54M
1
2
3 4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2018 Portfolio in Review

As of Q2 2018, Thomas Steyer held 115 positions worth $16.2B, up 12% from $14.4B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Thomas Steyer deployed $1.1B of net new capital in Q2 2018, opening 28 new positions and adding to 36 existing holdings. Its largest new stake was General Dynamics: 1,697,715 shares worth $316M.

By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 16% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was NXP Semiconductors, an estimated $618M trimmed.

  • Thomas Steyer's largest Q2 2018 buy was General Dynamics: 1,697,715 shares worth $316M.
  • Thomas Steyer added most to Altaba Inc in Q2 2018, an estimated $784M increase.
  • Thomas Steyer's biggest Q2 2018 reduction was NXP Semiconductors, cutting an estimated $618M.
  • Thomas Steyer fully exited Monsanto Co in Q2 2018, selling an estimated $543M.
  • Thomas Steyer's ten largest holdings make up 54% of its $16.2B portfolio in Q2 2018.
  • Thomas Steyer opened 28 new positions and closed 20 in Q2 2018.
  • Thomas Steyer's portfolio value rose 12% quarter-over-quarter to $16.2B.

Based on Farallon Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.